Search Results
Feb 24, 2026, 13:30 ET Direct Genome-Scale Mapping of Endonuclease Activity of the Human LINE-1 ORF2p Endonuclease
important work. We believe EGM is a powerful tool for directly measuring genome-scale DNA modifications, with the potential to significantly impact cell and gene therapy discovery and development."About Nabsys 2.0, LLCNabsys is advancing genomics with a clear focus on accessibility and innovation
More news about: Nabsys
Feb 24, 2026, 13:00 ET Walter Koroshetz Joins the Dana Foundation as Senior Advisor
also co-led a number of NIH Common Fund's programs, including the Undiagnosed Disease Network, the Acute to Chronic Pain Transition programs, Somatic Gene Editing program, and Somatic Mosaicism in Human Tissue. Koroshetz founded the BRAIN Initiative Neuroethics Working Group in 2015 and participated as
More news about: Dana Foundation
Feb 24, 2026, 12:26 ET Cox Business Teams Up with Best-Selling Author Gene Marks for "The AI Business Playbook"
announced the release of The AI Business Playbook, a guide for business leaders authored by acclaimed columnist and business management expert Gene Marks, featuring exclusive insights from Cox Business executives. The playbook equips organizations to develop a realistic, revenue-driving AI strategy
More news about: Cox Communications
Feb 24, 2026, 12:15 ET Illumina launches TruPath Genome, setting a new standard in genomic insight
University of Exeter shared data on their pilot of TruPath Genome, which found that the technology resolved highly complex genomic regions, including a gene known to be associated with inherited adrenal disorders. While current short-read WGS requires parental samples to identify compound heterozygotes,
More news about: Illumina, Inc.
Feb 24, 2026, 09:00 ET Kenai Therapeutics Appoints Blake Arnold, CFA, as Chief Business Officer
through roles of increasing responsibility at Novartis Gene Therapies (formerly AveXis, Inc.), ultimately serving as Head of Portfolio Innovation, New Products, and Business Development & Licensing, where he drove the pipeline growth strategy for the Gene Therapies business.Prior to joining Novartis,
More news about: Kenai Therapeutics/BIOCOM
Feb 24, 2026, 09:00 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2026 in REGENXBIO Lawsuit - RGNX
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: The Gross Law Firm
Feb 24, 2026, 08:53 ET Parks Associates' 30th CONNECTIONS™: The Premier Connected Home Conference, May 5-7 in Santa Clara, to Unite Industry Leaders on AI, Smart Energy, Security, Broadband, Insurance, and Next-Gen Connected Living
sustainability tech.Dennis Kyle, SVP, Smart Building, RealPage: smart building transformation and IoT convergence.Gene LaNois, VP, Business Development, Vivint, an NRG company: strategy for energy integration and connected services.John Mack,
More news about: Parks Associates
Feb 24, 2026, 08:30 ET Therna Biosciences Appoints Biotech Veteran Devyn Smith, Ph.D., to Board of Directors and Expands Strategic and Scientific Advisory Leadership
Board of Directors as an independent member. He currently serves as Chief Executive Officer and a member of the Board of Arbor Bio, a clinical stage gene editing company, since April 2021. He is a longtime board member and former Chairman of the Alliance for Regenerative Medicine (ARM) and advises multiple
More news about: Therna Biosciences
Feb 24, 2026, 08:00 ET Klotho Neurosciences (NASDAQ:KLTO) Initiates Development of the "Klotho Clock," a Diagnostic Biological Aging and Longevity Clock that Unlocks Health Testing Through Epigenetics and Artificial Intelligence (AI)
biologic age and the extent of DNA methylation of the human Klotho gene and promoter. Similar to many other human genes, the hypermethylation of the Klotho gene and its promoter are key events that occur over time that ultimately silence the gene and lower the Klotho protein levels in all tissues. Balancing
More news about: Klotho Neurosciences, Inc.
Feb 24, 2026, 08:00 ET Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash
both of which are elevated in patients with EGFRi-associated skin rash. The strain was then engineered to be safe by deleting an antibiotic resistance gene and engineering auxotrophy to control the growth of ATR04-484. Preclinical data have shown that ATR-04 can reduce levels of IL-36γ, a key pro-inflammatory
More news about: Azitra, Inc.
Feb 24, 2026, 07:00 ET Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting
Data, Identifying Patient and Disease Characteristics Associated with Best Outcomes in Retinitis Pigmentosa Patients Following MCO-010 Optogenetic Gene TherapyDALLAS, Feb. 24, 2026 /PRNewswire/ --
More news about: Nanoscope Therapeutics
Feb 24, 2026, 07:00 ET ARS Names Horizon Next Media AOR for Innovative Media and Marketing Strategies to Accelerate Customer Growth
platform.""Horizon's experience in home services and local-market media positions us to help ARS unlock greater value from video and location-based channels," said Gene Turner, President, Global Chief Client Officer, Horizon. "By combining strategic leadership with advanced analytics, we will help ARS drive more efficient
More news about: Horizon Media
Feb 24, 2026, 07:00 ET ERS Genomics launches new Early Access Express License
Laureate Professor Emmanuelle Charpentier, who, together with Dr Jennifer Doudna, was awarded the 2020 Nobel Prize in Chemistry for developing CRISPR/Cas9 gene-editing technology. The CVC portfolio represents the most comprehensive and widely granted collection of foundational CRISPR/Cas9 patents globally,
More news about: ERS Genomics
Feb 24, 2026, 06:02 ET Frontier Biotech and GSK Enter Global Exclusive Licensing Agreement for Small Interfering RNA Therapeutics
opportunity in the global pharmaceutical sector in recent years. siRNA therapies address three limitations of traditional drug development by enabling precise gene silencing of previously undruggable targets, delivering durable and highly specific efficacy, and providing a versatile platform applicable across a
More news about: Frontier Biotechnologies Inc.
Feb 24, 2026, 05:55 ET Frontier Biotech and GSK Enter Global Exclusive Licensing Agreement for Small Interfering RNA Therapeutics
opportunity in the global pharmaceutical sector in recent years. siRNA therapies address three limitations of traditional drug development by enabling precise gene silencing of previously undruggable targets, delivering durable and highly specific efficacy, and providing a versatile platform applicable across a
More news about: Frontier Biotechnologies Inc.
Feb 24, 2026, 03:04 ET Diamyd Medical announces finalization of database for interim analysis in Phase 3 DIAGNODE-3 trial
antigen-specific immune tolerance to GAD65 and preserve endogenous insulin production in individuals with type 1 diabetes who carry the HLA DR3-DQ2 gene. Retogatein has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 3 (clinically
More news about: Diamyd Medical AB
Feb 23, 2026, 12:00 ET New Gentle Methyl Conversion Kit Delivers High-Accuracy Profiling from as Little as 100 pg of DNA
Scientific Founder Professor Chuan He, Ellis Bio's portfolio goes beyond sequencing to provide insights into the DNA and RNA modifications that drive gene expression, collectively known as the epigenome and epitranscriptome. For more information, visit
More news about: Ellis Bio Inc
Feb 23, 2026, 10:30 ET Viral Vectors and Plasmid DNA Manufacturing Market to Reach $34.0 billion by 2033 at 20.4% CAGR: Allied Market Research
for R&D activities, surge in awareness regarding gene therapy, and rise in prevalence of cancer, viral infections, and genetic disorders drive the growth of the global viral vectors and plasmid DNA manufacturing market. However, high cost of gene therapies and risk of mutagenesis and other impediments
More news about: Allied Market Research
Feb 23, 2026, 09:36 ET NASDAQ: QURE INVESTOR ALERT: Berger Montague Advises uniQure N.V. (NASDAQ: QURE) Investors of an April 13, 2026 Deadline
CLICK HERE.uniQure, headquartered in Amsterdam, the Netherlands, is a biotechnology company focused on the development of gene therapies for severe diseases, including Huntington's disease (HD).The Complaint alleges that during the Class Period, Defendants
More news about: Berger Montague
Feb 23, 2026, 08:01 ET TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development
The data describe a template-driven RIG-I agonist strategy to selectively activate retinoic acid-inducible gene I (RIG-I) signaling inside tumor cells by leveraging overexpressed oncogenic microRNAs, such as miRNA-21, as intracellular assembly templates. This
More news about: TransCode Therapeutics, Inc.
Feb 23, 2026, 08:00 ET Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer
GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Japanese Patent Office has issued a favorable Appeal Decision to grant a patent claiming the use of Reqorsa® Gene Therapy in combination
More news about: Genprex, Inc.
Feb 23, 2026, 08:00 ET Ultima Genomics Introduces the Next Generation of Sequencing at Scale with the Launch of the UG200™ Series and Next Generation Solaris 2.0 Workflows Delivering Higher Output, Better Performance and More Flexible Wafer Configurations
UG 100 fleet in full production, handling over 100,000 whole genome samples a month," said Dr. Arjan Bormans, Chief Scientific Officer of Gene by Gene. "We only started using Ultima's new sample prep and amplification tech late last year, but it's held up - reliable, solid data, and easy to run.
More news about: Ultima Genomics
Feb 23, 2026, 07:00 ET PlantArcBio and Helix Sementes e Biotecnologia (Agroceres Group Company) Announce Licensing Collaboration to Advance High-Yield, Drought-Resilient Corn in South America
agronomic challenges faced by growers."About PlantArcBioPlantArcBio is an ag-biotechnology company developing proprietary gene discovery, gene-editing optimization, and RNAi-based technologies to enhance crop performance and sustainability. Through its patented DIP™ and DIPPER™ platforms,
More news about: PlantArcBio and Agroceres Group
Feb 20, 2026, 10:58 ET Discovery Could Make Immune Checkpoint Inhibitors Safer
healthy cardiac muscle cells as targets in addition to cancer cells. The team went on to show, in mice, that blocking TNF signaling specifically through the TNFR2 gene product prevented the inflammatory cycle from starting in the heart. "Checkpoint inhibitors allow TNF signaling to trigger CD8 T-cells that are
More news about: Cincinnati Children's Hospital Medical Center
Feb 20, 2026, 10:45 ET 'Functional Unemployment' Improves in January; Remains Up Year-Over-Year, Says Ludwig Institute
@LISEP_org.About Gene LudwigIn addition to his role as LISEP chair, Gene Ludwig is a managing partner of Canapi LLC, a financial technology venture fund. He is the founder and CEO of Ludwig
More news about: Ludwig Institute for Shared Economic Prosperity